Skip to main navigation Skip to search Skip to main content

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

  • International MG/COVID-19 Working Group

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)
Original languageEnglish
Pages (from-to)116803
JournalJournal of the Neurological Sciences
Volume412
DOIs
Publication statusPublished - 15 May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Betacoronavirus
  • COVID-19
  • Clinical Trials as Topic
  • Coronavirus Infections/complications
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Immunoglobulins, Intravenous/therapeutic use
  • Immunologic Factors/therapeutic use
  • Immunosuppressive Agents/therapeutic use
  • Immunotherapy
  • Lambert-Eaton Myasthenic Syndrome/complications
  • Myasthenia Gravis/complications
  • Pandemics
  • Plasma Exchange
  • Pneumonia, Viral/complications
  • SARS-CoV-2
  • Vaccines

Cite this